You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 285 No. 19, May 16, 2001 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (30)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Lipids and Lipid Disorders
 •Alert me on articles by topic

Updated Guidelines for Cholesterol Management

Michael S. Lauer, MD; Phil B. Fontanarosa, MD

JAMA. 2001;285:2508-2509.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

During the past decade, there has been tremendous progress in identifying novel risk factors and precisely delineating the role of traditional risk factors associated with coronary heart disease (CHD), with substantial research advances related to the role of lipoproteins and lipid metabolism. Observational studies have established the relationship of serum cholesterol and other lipoproteins with CHD in specific subgroups.1-3 Clinical trials have demonstrated convincing benefits of cholesterol lowering for reducing death and myocardial infarction among patients with CHD4-5 as well as beneficial effects of cholesterol lowering for decreasing the incidence of cardiac events in patients without established coronary disease.6-7 Accurately synthesizing and appropriately applying this rapidly accumulating evidence into clinical practice is essential for reducing the morbidity and mortality associated with coronary disease.

Thus, the Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel (Adult Treatment . . . [Full Text of this Article]

Author Affiliations: Dr Lauer is Contributing Editor and Dr Fontanarosa is Executive Deputy Editor, JAMA.


RELATED ARTICLE

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
JAMA. 2001;285(19):2486-2497.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diet and Primordial Prevention of Cardiovascular Disease in Children and Adolescents
Daniels
Circulation 2007;116:973-974.
FULL TEXT  

Primary Care Physicians' Knowledge and Practice Patterns in the Treatment of Chronic Kidney Disease: An Upstate New York Practice-based Research Network (UNYNET) Study
Fox et al.
J Am Board Fam Med 2006;19:54-61.
ABSTRACT | FULL TEXT  

Are Remnant-Like Particles Independent Predictors of Coronary Heart Disease Incidence?: The Honolulu Heart Study
Imke et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:1718-1722.
ABSTRACT | FULL TEXT  

Long-term statin use and psychological well-being
Young-Xu et al.
J Am Coll Cardiol 2003;42:690-697.
ABSTRACT | FULL TEXT  

Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
Grundy
Circulation 2002;106:2526-2529.
FULL TEXT  

Obesity, Metabolic Syndrome, and Coronary Atherosclerosis
Grundy
Circulation 2002;105:2696-2698.
FULL TEXT  

Aspirin for Primary Prevention of Coronary Events
Lauer
NEJM 2002;346:1468-1474.
FULL TEXT  

NCEP Guidelines for Cholesterol Management
Journal Watch Cardiology 2001;2001:1-1.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.